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The National Breast and Cervical Cancer Early Detection Pro-
gram (NBCCEDP) provides access to breast and cervical cancer
screening for low-income, uninsured, and underinsured women in
all states and US territories. In Idaho, a rural state with very low
breast and cervical cancer screening rates, this program is called
Women’s Health Check (WHC). The program has been operating
continuously since 1997 and served 4,719 enrollees in 2013. The
objective of this study was to assess whether disparities existed in
cause-specific survival (a net survival measure representing sur-
vival of a specified cause of death in the absence of other causes
of death) between women screened by WHC and outside WHC
and to determine how type of surgery or survival varies with stage
at diagnosis.
Methods
WHC data were linked to Idaho’s central cancer registry to com-
pare stage distribution, type of surgery, and cause-specific surviv-
al between women with WHC-linked breast cancer and a compar-
ison group of women whose records did not link to the WHC data-
base (nonlinked breast cancer).
Results
WHC-linked breast cancer was significantly more likely to be dia-
gnosed at a later stage of disease than nonlinked breast cancer. Be-
cause of differences in stage distribution between WHC-linked
and nonlinked breast cancers, overall age-standardized, cause-spe-
cific breast cancer survival proportions diverged over time, with a
5.1 percentage-point deficit in survival among WHC-linked cases
at 5 years of follow-up (83.9% vs 89.0%). Differences in type of
surgery and cause-specific survival were attenuated when con-
trolling for stage.
Conclusion
This study suggests that disparities may exist for Idaho WHC en-
rollees in the timely diagnosis of breast cancer. To our knowledge,
this is  the first  study to publish comparisons of cause-specific
breast cancer survival between NBCCEDP-linked and nonlinked
cases.
Introduction
The Breast and Cervical Cancer Mortality Prevention Act of 1990
(Public Law 101–354) directed the Centers for Disease Control
and Prevention (CDC) to create the National Breast and Cervical
Cancer Early Detection Program (NBCCEDP), which increases
access to breast and cervical cancer screening and detection ser-
vices for low income, uninsured, and underinsured women (1,2).
Women’s Health Check (WHC), Idaho’s breast and cervical can-
cer early detection program, is funded through NBCCEDP and
state legislative appropriations (3).
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Idaho’s WHC program primarily serves women who are US cit-
izens or noncitizens who have lived in the United States for 5 or
more  years,  have  incomes  up  to  200% of  the  federal  poverty
guidelines, and have no health insurance coverage for Papanicol-
aou (Pap) tests or mammograms (3). WHC provides Pap tests for
women aged 40 to 64 years every 3 years, or every 5 years with a
human  papillomavirus  (HPV)  co-test;  it  provides  an  annual
screening mammogram for women aged 50 to 64 years, plus a
clinical breast examination. In addition, WHC offers limited en-
rollment and screening for women who meet income and insur-
ance status requirements beginning at age 30 if they are sympto-
matic for breast or cervical cancer. Women older than 65 who are
not eligible for Medicare or cannot afford Medicare Part B are also
eligible for WHC screening. The WHC program has operated con-
tinuously since 1997, and during fiscal year 2013 it had 4,719 wo-
men enrolled in the program (3). Women with breast or cervical
cancer or precancerous conditions who were enrolled in WHC be-
fore a tissue biopsy diagnosis can qualify for treatment through the
Idaho Medicaid Breast and Cervical Cancer Program.
The Cancer Data Registry of Idaho (CDRI) is a population-based
cancer registry that collects incidence and survival data on all can-
cer patients who reside in the state of Idaho or who are diagnosed
or treated for cancer in the state (4). CDRI meets program stand-
ards of the National Program of Cancer Registries and is recog-
nized as a “gold standard” registry for data quality, completeness,
and timeliness as designated by the North American Association
of Central Cancer Registries (5,6). Since 1999, CDRI has linked
with the WHC database to identify potentially missed breast can-
cers in the CDRI database, reconcile differences between the 2
systems, and update appropriate data fields to capture post-link-
age information (7). This study compared stage distribution, type
of surgery, and survival between women with WHC-linked breast
cancer diagnosed during the period 2004–2012 and a comparison
group of women whose records did not link to the WHC database
(nonlinked  breast  cancer).The  study  followed  comparisons
between NBCCEDP-linked breast  cancer  cases  and nonlinked
breast  cancer  cases  on  stage  at  diagnosis  (8–12),  treatment
(9,11–13), and mortality (12).Survival rates are a crucial metric
for evaluating advances in treatment and measuring differences in
outcomes between populations; however, net measures of cancer
survival are lacking for women diagnosed through the NBCCEDP.
The objective of this study was to assess whether disparities exist
in cause-specific survival (a net survival measure representing sur-
vival of a specified cause of death in the absence of other causes
of death) between women with WHC-linked and women with non-
linked breast cancers and to understand how differences in type of
surgery or survival are related to stage at diagnosis. To our know-
ledge, this is the first study to publish comparisons of cause-spe-
cific  breast  cancer  survival  between women with NBCCEDP-
linked and women with nonlinked cases.
Methods
WHC uses CaST software (Information Management Services,
Inc) provided by CDC to NBCCEDP grantees for data collection,
database management, and reporting. Details of CDRI’s data col-
lection procedures and coding rule use were previously reported
(4).  At  least  once  per  year  since  1999,  data  have  been linked
between WHC and CDRI databases by using probabilistic linkage
software, currently Link Plus, version 2.0 (CDC) (7). This study
used CDRI cases diagnosed from 2004 through 2012 that were
linked to WHC in November 2013. Because this project classified
as program evaluation by the Idaho Department of Health and
Welfare Research Determination Committee, it was exempt from
institutional review board review.
This study was limited to Idaho resident women aged 30 to 64
years who were diagnosed with breast cancer from 2004 through
2012 identified from the CDRI database, who were linked to the
WHC database (WHC-linked) and a comparison group of women
with the same date and age at diagnosis criteria whose records did
not link to the WHC database (nonlinked). Breast cancers repor-
ted solely by death certificates were excluded from analyses of
stage,  treatment type,  and survival.  Type of breast  surgery in-
cluded breast-conserving surgery (Facility  Oncology Registry
Data Standards [FORDS] codes 20–24) and mastectomy (FORDS
codes 30–80) (14).
Statistical analyses were conducted using SEER*Stat version 8.1.5
(Information Management Services,  Inc)  and SAS version 9.3
(SAS Institute Inc). Pearson χ2 statistics were used to test associ-
ations between cross-frequencies of variables, and Cochran–Man-
tel–Haenszel statistics were used in the analysis of stratified cat-
egorical  data.  We used t  tests  to compare differences between
mean ages. P values less than .05 were considered to be signific-
ant. For analyses using stage distribution as the outcome variable,
cancers with unknown stage at diagnosis were excluded from stat-
istical tests. For analyses using type of surgery as the outcome
variable, cancers of unknown stage or with associated surgery that
was either unspecified or unknown were excluded from statistical
tests.
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The survival statistics in this study were not designed to be repres-
entative of death rates among women with breast cancer, which
would also include other causes of death, but rather to facilitate the
comparison of  WHC-linked and nonlinked groups in  terms of
death from breast cancer. To ascertain deaths related to a specific
cancer  site  (ie,  breast  cancer)  but  not  coded to the underlying
cause of death, we used the Surveillance, Epidemiology and End
Results (SEER) cause-specific death classification to account for
causes of death in conjunction with tumor sequence (ie, only 1 tu-
mor or the first of subsequent tumors), site of the original cancer
diagnosis, and comorbidities (15). Cause-specific survival was cal-
culated by using the actuarial method for women diagnosed with
invasive breast cancer from 2004 through 2010, with breast can-
cer as the first or only primary cancer, who were aged 30 to 64
years at the time of diagnosis. The end of the study period for sur-
vival analyses was set at December 31, 2011, because that is the
latest date for which death data were complete. At the time of this
study, CDRI had linked all 2004–2011 cancers to state death re-
cords from 2004 through 2012 and had conducted National Death
Index searches for 2004 through 2011 (16). Women who were not
known to be deceased as of December 31, 2011, were presumed
alive on this date for survival calculations (17). Survival estimates
were age-standardized to the International Cancer Survival Stand-
ard using the age groups 30 to 39 years, 40 to 49, and 50 to 64
(18).
Results
From 2004 through 2012, a total  of 5,606 in situ and invasive
breast cancers were diagnosed among Idaho resident women aged
30 to 64 years and were used in the linkage to the WHC database.
Of these, 540 (9.6%) breast cancers linked to WHC. Nine breast
cancers were reported solely by death certificates, none of which
linked to WHC; these were excluded from analyses of stage, type
of surgery, and survival. No cancer record had missing informa-
tion on age at diagnosis. Thirty-nine records were missing stage
information (3 among WHC-linked cancers and 36 among non-
linked cancers) and were excluded from analyses of stage and type
of surgery. Twelve records were missing information on type of
surgery (0 among WHC-linked cancers and 12 among nonlinked
cancers) and were excluded from analysis of surgery type.
The age distribution of the WHC-linked cancers was significantly
different from the nonlinked cancers (P = .02); women with WHC-
linked cancers were slightly younger (P = .01 [Table 1]).  The
mean ages of women in the 2 groups were less than 1 year apart.
Women with WHC-linked cancers were significantly more likely
to be diagnosed at a later stage than women with nonlinked can-
cers (43.4% vs 31.3% at regional or distant stage, P < .001), even
after controlling for age differences between the 2 groups. In age
groups for which population-based breast cancer screening is of-
ten recommended (40–49 y and 50–64 y), the WHC-linked can-
cers were significantly more likely to be diagnosed at a later stage
(40–49 y, 45.4% vs 33.7%, P = .003; 50–64 y, 40.9% vs 29.1%,  P
< .001). Among women 30 to 39 years, for whom breast cancer
screening is not recommended, there was no significant relation-
ship between WHC linkage status and stage (P = .14).
Table 2 presents first course of surgery by stage at diagnosis and
WHC linkage status. Overall, women with WHC-linked cancers
were significantly less likely to have breast-conserving surgery
(52.3% vs 59.0%, P = .01), but this relationship was attenuated
when adjusting for stage (P = .36). Stratified by stage, there was
no significant relationship between type of surgery and WHC link-
age status (P = .34 for in situ, P = .34 for localized, P = .61 for re-
gional, and P = .34 for distant).
By stage at diagnosis, there were no significant differences in age-
standardized, cause-specific breast cancer survival proportions
between women with WHC-linked cancers and women with non-
linked cancers at 1 to 5 years of follow-up (Table 3). However, be-
cause of differences in stage distribution between WHC-linked
and nonlinked cancers, overall age-standardized, cause-specific
breast cancer survival proportions diverged over time, with a 5.1
percentage-point deficit in survival among women with WHC-
linked cancers at 5 years of follow-up (83.9% vs 89.0%).
Discussion
The Idaho WHC program began in 1997, with a focus on target-
ing medically underserved and symptomatic women for screening
for  breast  and  cervical  cancers.  Consistent  with  national
NBCCEDP estimates (1), fewer than 15% of Idaho’s WHC-eli-
gible women are currently served by the program. In 2012, an es-
timated 246,645 women in Idaho were aged 40 to 64 years; 69,566
had incomes below 200% of federal poverty guidelines, of whom
28,484 (40.9%) were uninsured (19). Some additional women had
health insurance but were uninsured for breast or cervical cancer
screening. The percentage of Idaho women who had incomes be-
low 200% of the federal poverty guidelines and were uninsured
differed by age: 13.4% of women aged 40 to 49 years and 10.4%
of women aged 50 to 64 years (19). Younger women were some-
what overrepresented in the WHC program, as illustrated by the
younger age distribution of the WHC-linked breast cancers com-
pared with nonlinked cancers.
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Age-appropriate  screening for  breast  and cervical  cancers  has
helped reduce death rates from these diseases. The US Preventive
Services Task Force currently recommends biennial  screening
mammography for  women aged 50  to  74  years  (20).  In  2012,
Idaho ranked 50th among states and the District of Columbia in
the proportion of women aged 40 years or older and aged 50 to 74
who had received a screening mammogram for breast cancer with-
in  the  previous  2  years  (21).  From 2008 through 2012,  WHC
provided mammograms to 10,112 women and Pap tests to 8,491
women (22). However, since the WHC program began in Idaho,
overall screening trends for breast and cervical cancer have essen-
tially  remained  flat  (21).  Because  state  programs  under  the
NBCCEDP cover relatively small proportions of the total age-ap-
propriate screening populations, the signal related to these pro-
grams may be lost in the noise inherent to population-based sur-
veys.
Despite Idaho’s low cancer screening rates, which may act to min-
imize differences, this study was able to detect significant differ-
ences between WHC-linked breast cancers and nonlinked breast
cancers. A main finding of this study is that from 2004 through
2012, among women of ages for which breast cancer screening is
recommended, WHC-linked cases of breast cancer were signific-
antly more likely than nonlinked cancers to be diagnosed at a later
stage of disease. This outcome has not been consistently found in
comparable studies of state breast and cervical cancer programs.
As in Idaho, breast cancers among NBCCEDP enrollees in Flor-
ida and Nebraska were significantly more likely to be diagnosed at
a later stage (8,12). However, 2 studies of the equivalent program
in Massachusetts found that stage at diagnosis of program parti-
cipants did not differ significantly from comparison groups (9,10).
The differences in these results by state may be related to popula-
tion screening prevalence. In 2012, likely because of the effect of
state-based  health  care  reform efforts,  Massachusetts  had  the
highest rate of mammography screening in the United States (21).
Florida and Nebraska, like Idaho, were below the national median.
We speculate that 1 reason for the increased likelihood of late-
stage breast cancer diagnosis is that WHC is not only a screening
program but also serves women who have symptoms suspicious of
breast or cervical cancer as confirmed by a health care profession-
al. Other states have noted that the majority of women coming in-
to the NBCCEDP program and being screened entered the pro-
gram because they were symptomatic (8). Of all invasive cancers
detected in the Idaho WHC program from 2009 through 2012,
one-third were diagnosed because of referral into the program be-
cause of abnormal screening results outside the program, and al-
most another one-third were diagnosed among women whose ini-
tial WHC mammogram was for evaluation of symptoms (WHC,
unpublished data). In the general population, a higher proportion
of breast cancer diagnoses may result from screening of asympto-
matic women in the age group 40 to 64 and hence have been de-
tected at an earlier stage. Other reasons why WHC participants in
Idaho have an increased likelihood of late-stage breast cancer may
be differences in tumor biology, delayed diagnosis, and higher
rates of over-diagnosis among nonparticipants (23).
Other studies have shown that information on type of surgery in
cancer registries is nearly complete, whereas data on chemother-
apy and radiation therapy may be incomplete (24). The surgical
treatment data in this study were nearly complete and were com-
parable to data from the SEER program (25). In SEER registries,
the percentage of female breast cancers with no surgery coded or
unknown surgery codes was less than 4% for in situ and localized
stage and less than 3% for regional stage. Among Idaho breast and
cervical cancers in this study, less than 5% of in situ and regional
breast cancers and less than 3% of localized cancers had no sur-
gery coded or unknown surgery codes.
Women diagnosed with early-stage invasive breast cancer in the
United States  typically have either  mastectomy or  breast-con-
serving surgery in combination with radiation therapy. Both op-
tions are equally effective in terms of survival (26). In this study,
we found a significant difference in 5-year cause-specific survival
from breast cancer between WHC-linked cancers and nonlinked
cancers but not when stratified by stage at diagnosis. The overall
difference in survival may be related to potential lead-time bias
among the nonlinked cases. There may have been an increase in
the time from diagnosis to survival outcome because the preclinic-
al detection time was included in survival calculations, but there
may be no change in the type or date of the outcome. The stage-
specific survival results suggest that outcomes were similar for
WHC-linked and nonlinked cases after diagnosis.  As with our
cause-specific survival results stratified by stage, Bhuyan et al
used logistic regression in Nebraska to model all-cause deaths at 1
and 5 years after breast cancer diagnosis and found the adjusted
odds of death did not differ significantly between NBCCEDP can-
cers and non-NBCCEDP cancers (12).
Our results indicate that women with WHC-linked breast cancer
appeared to receive the same level of care as those with nonlinked
cancers. For both WHC-linked and nonlinked cancers, about 80%
of women were treated in Idaho hospitals accredited by the Amer-
ican College of Surgeons Commission on Cancer (27). Twenty-
five surgeons in Idaho performed about 70% of all breast cancer
surgeries  in  the  study population,  both for  WHC-linked cases
(68%) and nonlinked cases (70%). For individual surgeons, the
proportion of cases that were WHC-linked differed depending on
the percentage of their services that were covered by Medicaid.
Differences in type of surgery and survival observed in this study
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were probably the result of differences in stage at diagnosis. Ad-
justing for stage,  we found no significant differences between
WHC-linked and nonlinked cancers in type of surgery or breast
cancer cause-specific survival. Again, differences in stage distri-
bution between WHC-linked and nonlinked cancers should not ne-
cessarily be construed as a health care disparity because WHC is
not strictly a screening program.
Limitations of the routinely collected surveillance data used in this
study include a lack of detailed information on women that may
have influenced treatment planned or received. Information was
not available on pregnancy status, family history, prior medical
history, or tumor margins. In addition, the study did not include a
review of hormone receptor status, biomarkers, genetic testing res-
ults, or presence of other disorders. Because of concerns about
data quality, neither radiation therapy nor chemotherapy regimens
were reported in this study (24). Another potential limitation is the
relatively small number of linked cases, which resulted in limited
power to detect  differences between WHC-linked cancers and
nonlinked cancers. Strengths of this study include use of high-
quality data from CDRI and WHC with a low proportion of un-
known or missing values for the variables studied and a long his-
tory of successful linkages between the 2 databases.
A potential limitation of our study is that the comparison group
should  have  more  closely  reflected  the  socioeconomic  status
(SES) of the WHC-linked cases. Individual-level measures of SES
are not collected by central cancer registries and are thus not avail-
able for analysis. For the data set used in this study, a census tract-
based SES measure of the percentage of the population with in-
comes below federal poverty guidelines was available for cancers
diagnosed from 2004 through 2011. The distributions of stage at
diagnosis and type of surgery did not differ significantly by area-
based SES. Likewise, stage-specific survival did not differ signi-
ficantly by area-based SES. Hence, additional results were not re-
ported by area-based SES.
This is the first study to show a breast cancer survival disparity for
the NBCCEDP population. Because of differences in stage at dia-
gnosis, this study found that women with WHC-linked cancers
were significantly less likely to have breast-conserving surgery
and significantly more likely to die of their cancer within 5 years
of diagnosis. The findings suggest that WHC is working as inten-
ded by focusing on symptomatic or rarely or never screened wo-
men who are at greater risk for late-stage cancers. The Idaho Divi-
sion of Public Health will use these results to attempt to increase
the number of new clients who are rarely or never screened, focus-
ing on the reservoir of undiagnosed prevalent cancers. These find-
ings reinforce the necessity of screening women from our priority
population given the likelihood of later stage disease and lower
survival rates among WHC-linked cancers. These findings will
help inform future outreach efforts as well as provide a metric for
future evaluation of screening in our priority population. Findings
also reinforce the importance of patient outreach, education, and
navigation. Potential strategies for maximizing the efficacy of the
WHC program include biennial versus annual screening intervals
for mammograms and securing nonfederal funding with flexibil-
ity in resource allocation. Such funding could be used to perform
outreach and effect system changes, such as innovative data col-
lection and increased use of evidence-based strategies in all as-
pects of WHC program implementation, including patient remind-
ers, one-on-one counseling, tailored small-media outreach, and
better use of community–clinical linkages to increase enrollment.
This study suggests that health care disparities may exist for Idaho
WHC enrollees in the timely diagnosis of breast cancer and that
these disparities drive overall differences in type of surgery and
cause-specific survival. This study also illustrates the power of
linkages between central cancer registries and NBCCEDP data-
bases for quality improvement, program assessment, and monitor-
ing population health. Future studies should attempt to identify the
reasons for the identified breast cancer disparities. Methods for
doing so may include surveys of NBCCEDP participants to assess
delayed diagnosis and patterns-of-care studies that include addi-
tional patient characteristics, tumor biology, and treatment data.
The  WHC program is  important  because  of  Idaho’s  very  low
breast and cervical cancer screening rates.
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Tables
Table 1. Breast Cancers in Idaho Resident Women (In Situ and Invasive) by WHC Linkage Status and Age and Stage at
Diagnosis, 2004–2012
Age and Cancer Stage at Diagnosis WHC-Linked Cancera Nonlinked Cancera P Valueb
5-year age group, y
30–34 18 (3.3) 82 (1.6)
 .02
35–39 16 (3.0) 211 (4.2)
40–44 62 (11.5) 487 (9.6)
45–49 101 (18.7) 861 (17.0)
50–54 113 (20.9) 1,039 (20.5)
55–59 116 (21.5) 1,154 (22.8)
60–64 114 (21.1) 1,232 (24.3)
Mean age, y 52.0 52.9 .01
All ages
In situ or localized 304 (56.6) 3,451 (68.7)
<.001
Regional or distant 233 (43.4) 1,570 (31.3)
Aged 30–39 y
In situ or localized 14 (41.2) 158 (54.5)
.14
Regional or distant 20 (58.8) 132 (45.5)
Aged 40–49 y
In situ or localized 89 (54.6) 885 (66.3) .003
Regional or distant 74 (45.4) 450 (33.7)
Aged 50–64 y
In situ or localized 201 (59.1) 2,408 (70.9)
<.001
Regional or distant 139 (40.9) 988 (29.1)
Abbreviation: WHC, Women’s Health Check.
a Values are N (%) unless otherwise indicated.
b Pearson χ2 statistics were used to test associations between cross-frequencies of variables, and t tests were used to compare differences between
mean ages. P values <.05 were considered to be  significant. Cancers of unknown stage were excluded from tabulations and statistical tests.
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Table 2. Type of Surgery by WHC Linkage Status and Stage at Diagnosis, Breast Cancer in Idaho Resident Women,
2004–2012
Cancer Stage at Diagnosis and
Type of Surgery WHC-Linked Cancers, N (%)a Nonlinked Cancers, N (%)a P Valueb
All stages
No surgery 36 (6.7) 269 (5.4)
.01Breast conserving surgery 281 (52.3) 2,954 (59.0)
Mastectomy 220 (41.0) 1,786 (35.7)
In situ
No surgery 5 (7.4) 46 (4.4)
.34Breast conserving surgery 48 (70.6) 707 (67.5)
Mastectomy 15 (22.1) 295 (28.1)
Localized
No surgery 5 (2.1) 46 (1.9)
.34Breast conserving surgery 150 (63.6) 1,634 (68.2)
Mastectomy 81 (34.3) 715 (29.9)
Regional
No surgery 9 (4.6) 65 (4.7)
.61Breast conserving surgery 77 (39.3) 590 (42.9)
Mastectomy 110 (56.1) 721 (52.4)
Distant
No surgery 17 (45.9) 112 (58.9)
.34Breast conserving surgery 6 (16.2) 23 (12.1)
Mastectomy 14 (37.8) 55 (28.9)
Abbreviations: WHC, Women’s Health Check.
a Percentages may not sum to 100% because of rounding.
b Pearson χ2statistics were used to test associations between cross-frequencies of variables. P values <.05 were considered to be significant. Cancers
with unknown stage or unspecified or unknown surgery were excluded from tabulations and statistical tests.
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Table 3. Age-Standardized, Cause-Specific Breast Cancera Survival Proportions by WHC Linkage Status and Stage at Dia-









N % (95% CI)c N % (95% CI)c





2 94.0 (90.3–96.4) 95.9 (95.1–96.6)
3 91.9 (87.8–94.7) 93.5 (92.4–94.4)
4 88.1 (82.8–91.9) 90.7 (89.3–91.9)






2 98.4 (94.6–99.5) 98.9 (98.2–99.3)
3 98.4 (94.6–99.5) 97.9 (97.0–98.6)
4 97.7 (93.6–99.2) 96.7 (95.5–97.6)






2 93.7 (86.6–97.1) 95.1 (93.4–96.4)
3 88.7 (80.8–93.5) 92.1 (89.9–93.8)
4 85.0 (75.2–91.2) 88.1 (85.5–90.3)






2 69.7 (47.2–84.1) 67.6 (58.2–75.3)
3 69.7 (47.2–84.1) 51.5 (41.8–60.4)
4 51.0 (29.4–69.0) 40.4 (30.8–49.8)
5 39.4 (17.0–61.3) 37.8 (28.2–47.3)
Abbreviations: CI, confidence interval; NC, could not be calculated; WHC, Women’s Health Check.
a Cause-specific breast cancer survival is a net survival measure representing survival of a specified cause of death in the absence of other causes of
death.
b First primary cases with follow-up through December 2011. Survival calculations use actuarial method. Age standardized to the International Cancer
Survival Standard 1, with age groups 30–39 y, 40–49 y, 50–64 y (18).
c 95% CIs use complementary log–log transformation.
d Total includes cases with unknown stage.
PREVENTING CHRONIC DISEASE VOLUME 12, E36
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY         MARCH 2015
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
10       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2015/14_0439.htm
